Men & Their Families Encouraged to Take the PSA Pledge

ClevelandDx will Donate to ZERO Prostate Cancer for Every Pledge Made at PSAonPSA.com

Cleveland Diagnostics, Inc., a pioneering precision oncology company, relaunches its third annual PSA on PSA Campaign this September for Prostate Cancer Awareness Month with a powerful new message: Take the PSA Pledge.

Short for a Public Service Announcement on the Prostate-Specific Antigen test, the national PSA on PSA campaign aims to move beyond awareness and into action in its third year. This year, men and their loved ones are encouraged to start a conversation about prostate cancer risk and screening. For every pledge made at PSAonPSA.com, ClevelandDx will donate to ZERO Prostate Cancer to support patient education and resources. Throughout September, ZERO will also match all donations to double the impact.

“Prostate cancer is very treatable when caught early, yet too many men are still diagnosed at later stages,” said Arnon Chait, PhD, President and CEO of ClevelandDx. “This year’s campaign is all about helping people take the first, often hardest, step of starting the conversation. The inspiration for this call-to-action stems back to a much-needed shift in approach from reactive to proactive when it comes to cancer diagnostics. The action of taking the PSA Pledge is simple, but it has the power to enact big change.”

The PSA Pledge is open to everyone—men and their partners, families, friends, or caregivers—and represents a commitment to either talking with their doctor or encouraging someone they love to do the same. The PSA on PSA website is filled with trusted resources, helpful questions to guide conversations, and information to better understand risk, screening, and testing options.

“I can’t overstate how important early, accurate detection is in improving patient outcomes,” shared Dr. Jason Hafron, Chief Medical Officer and Medical Director of Clinical Research at Michigan Institute of Urology. “Each year, the PSA on PSA Campaign helps spark conversations and educate people on prostate cancer risk. I’m particularly excited about the impact of this ‘Take the Pledge’ iteration. Increasing accountability when it comes to timely screening is a big hurdle in our field.”

Prostate cancer remains the second most common cancer in American men, with 1 in every 8 men diagnosed during their lifetime, according to the American Cancer Society. Screening typically starts at age 50 or as early as 40 for those at higher risk and is recommended every two years unless a high PSA level is detected. An elevated PSA typically leads to follow up testing, ranging from blood tests to biopsies, with varying levels of invasiveness and accuracy.

Cleveland Diagnostics’ mission is to detect cancer earlier and more accurately through the development of novel diagnostic tests. Its flagship IsoPSA® prostate cancer test analyzes protein structure to provide greater insight into patients’ elevated PSA levels. The blood test helps determine if patients’ PSA proteins originated in cancer cells. This valuable information can lead to early cancer detection in many patients while helping others avoid potentially unnecessary and invasive testing.

IsoPSA is covered by Medicare and a growing number of commercial plans, and is available for physicians to order directly through ClevelandDx or Quest Diagnostics. New research continues to support the test’s performance and accuracy, with recent longitudinal data in Urology validating the predictive value of IsoPSA’s results over time. Another recent study in Journal of Urology demonstrated IsoPSA’s ability to accurately detect clinically significant prostate cancer across racial groups.

Visit PSAonPSA.com to learn more, take the PSA Pledge, and access resources.

About Cleveland Diagnostics, Inc.

Cleveland Diagnostics is a precision oncology company focused on changing the shape of cancer detection. The company has unlocked the diagnostic power of protein structure with its revolutionary IsoClear™ platform that enables novel diagnostics based on a single cancer-specific, protein structure-based assessment using easy to execute tests within the clinical lab setting. Learn more at ClevelandDx.com and IsoPSA.com.

About ZERO Prostate Cancer

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 85 cents of every dollar to research and programs. Learn more at zerocancer.org

View source version on businesswire.com: https://www.businesswire.com/news/home/20250826619581/en/

For every pledge made at PSAonPSA.com, ClevelandDx will donate to ZERO Prostate Cancer to support patient education and resources.